Annovis Bio, Inc. (ANVS) Stock Research
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Latest price: 0.8449 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Hoffman Michael B | buy | 2026-11-06 | 5000000 |
| Hoffman Michael B | buy | 2026-05-20 | 104367.21 |
| Hoffman Michael B | buy | 2026-05-20 | 4483.5 |
| Hoffman Michael B | buy | 2026-05-20 | 33928.2 |
| Hoffman Michael B | buy | 2026-04-02 | 1498980 |
| Hoffman Michael B | buy | 2025-12-08 | 63600 |
| Hoffman Michael B | buy | 2025-12-08 | 130194 |
| Hoffman Michael B | buy | 2025-11-24 | 116598.4 |
| Hoffman Michael B | buy | 2025-11-24 | 35420 |
| Hoffman Michael B | buy | 2025-11-24 | 6149.57 |